Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing
July 27, 2026
Neuropathix, Inc. Welcomes Daniele Piomelli, PhD, MD to the Company’s Scientific Advisory Board
January 25, 2022
Related Post
-
-
NorthStrive Defense Tech Engages Defense Software and Security Firm Deploy360 to Validate Patented GPS-Denied Drone Navigation Technology Under Option to License
July 27, 2026
-
MannKind Announces FDA Approval of Furoscix ReadyFlow(TM), the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease
July 24, 2026
-
BiomX Subsidiary Zorronet Expands European Presence Through Two Strategic Collaborations in Europe
July 24, 2026